Cold air plasma improving rheumatoid arthritis via mitochondrial apoptosis pathway
Author(s) -
Ding Chengbiao,
Ni Leying,
Liu Qi,
Zhou Chenxu,
Wang Guomin,
Chu Paul K.,
Wu Zhengwei
Publication year - 2023
Publication title -
bioengineering and translational medicine
Language(s) - English
Resource type - Journals
ISSN - 2380-6761
DOI - 10.1002/btm2.10366
Subject(s) - rheumatoid arthritis , apoptosis , angiogenesis , cancer research , reactive oxygen species , ex vivo , medicine , arthritis , infiltration (hvac) , fibroblast , mitochondrial ros , immunology , in vivo , chemistry , biology , microbiology and biotechnology , in vitro , biochemistry , materials science , composite material
Abstract Rheumatoid arthritis (RA) has plagued physicians and patients for years due to the lack of targeted treatment. In this study, inspired by the commonality between rheumatoid arthritis fibroblast‐like synoviocytes (RA‐FLS) and cancer cells, the therapeutic effects of cold air plasma (CAP) on RA are studied systematically and thoroughly. In/ex vivo results show that CAP with the proper dosage significantly relieves symptoms including synovial hyperplasia, inflammatory infiltration, and angiogenesis and eliminates the root cause by triggering the self‐antioxidant capability of the surrounding tissue. The mechanism on the molecular and cellular level is also revealed that the spontaneous reactive oxygen species (ROS) cascade induces the mitochondrial apoptosis pathway on RA‐FLS. This study reveals a new strategy for targeted treatment of RA and the mechanistic study provides the theoretical foundation for future development of plasma medicine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom